COX-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity

European Journal of Gynaecological Oncology

Volumn 30, Issue 5, 2009, Pages 531-535

  Menczer, J ^a   Schreiber, L ^a   Kravtsov, V ^a   Berger, E ^a   Golan, A ^a   Levy, T ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

COX 2 expression; Epithelial ovarian carcinoma; Platin sensitivity; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG SENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PARAMETER; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL TIME; TISSUE SECTION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 70350066161     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Tsujii M., DuBois R.N.: "Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2". Cell, 1995, 83, 493.
2. Cao Y., Prescott S.M.: "Many actions of cyclooxygenase-2 in cellular dynamics and in cancer". J. Cell Physiol., 2002, 190, 279. (Pubitemid 34111968)
3. Matsumoto Y., Ishiko O., Deguchi M., Nakagawa E., Ogita S.: "Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms". Int. J. Mol. Med., 2001, 8, 31.
4. Klimp A.H., Hollema H., Kempinga C., van der Zee A.G., de Vries E.G., Daemen T.: "Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages". Cancer Res., 2001, 61, 7305.
5. Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M. et al.: "Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma". Am. J. Pathol., 2002, 60, 893. (Pubitemid 34224579)
6. Ferrandina G., Ranelletti F.O., Lauriola L., Fanfani F., Legge F., Mottolese M. et al.: "Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and her 2/neu expression in ovarian cancer". Gynecol. Oncol., 2002, 85, 305. (Pubitemid 34522990)
7. Ferrandina G., Lauriola L., Zannoni G.F., Fagotti A., Fanfani F., Legge F. et al.: "Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients". Ann. Oncol., 2002, 13, 1205. (Pubitemid 34141840)
8. Landen C.N. Jr., Mathur S.P., Richardson M.S., Creasman W.T.: Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies". Am. J. Obstet. Gynecol., 2003, 188, 1174.
9. Shigemasa K., Tian X., Gu L., Shiroyama Y., Nagai N., Ohama K.: Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas". Int. J. Oncol., 2003, 22, 99.
10. Erkinheimo T.L., Lassus H., Finne P., van Rees B.P., Leminen A., Ylikorkala O. et al.: "Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER 2/neu, and poor outcome in serous ovarian carcinoma". Clin. Cancer. Res., 2004, 10, 538.
11. Khalifeh I., Munkarah A., Lonardo F., Malone J.M., Morris R., Lawrence W.D. et al.: "Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma". Int. J. Gynecol. Pathol., 2004, 23, 162. (Pubitemid 38391776)
12. Seo S.S., Song Y.S., Kang D.H., Park I.A., Bang Y.J., Kang S.B. et al.: "Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer". Gynecol. Oncol., 2004, 92, 927.
13. Singhal P.K., Spiegel G., Driscoll D., Odunsi K., Lele S., Rodabaugh K.J.: "Cyclooxygenase 2 expression in serous tumors of me ovary". Int. J. Gynecol. Pathol., 2005, 24, 62. (Pubitemid 40066454)
14. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei G.L.: "Expression of inducible nitric oxide synthase and cycloxygenase-2 in ovarian cancer: correlation with clinical outcome". Gynecol. Oncol., 2004, 92, 806. (Pubitemid 38251381)
15. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Tadei C.L.: "Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival". Int. J. Gynecol. Cancer, 2005, 15, 255. (Pubitemid 40396961)
16. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Taddei G.L.: "COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer". Acta Obstet. Gynecol. Scand., 2006, 85, 493.
17. Ozel E., Pestereli H.E., Simsek T., Erdogan G., Karaveli F.S.: Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?". Int. J. Gynecol. Cancer, 2006, 16, 549.
18. Sorensen H.T., Friis S., Norgard B., Mllemkjaer L., Blot W.J., McLaughlin J.K. et al.: "Risk of cancer in a large cohort of nonaspirin NSAID users: a population based study". Br. J. Cancer, 2003, 88, 1687. (Pubitemid 36760410)
19. Lacey J.V. Jr., Sherman M.E., Hartge P., Schatzkin A., Schairer C.: "Medication use and risk of ovarian carcinoma: a prospective study". Int. J. Cancer, 2004, 108, 281. (Pubitemid 37541784)
20. Ozols R.F.: "Systemic therapy for ovarian cancer: current status and new treatments". Semin. Oncol., 2006, 33, S3.
21. Barda G., Menczer J., Chetrit A., Lubin F., Beck D., Piura B. et al.: Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study". Am. J. Obstet. Gynecol., 2004, 190, 1039.
22. Ozols R.F.: "Recurrent ovarian cancer: evidence-based treatment". J. Clin. Oncol., 2002, 20, 1161.
23. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S. et al.: "Second-line platinum therapy in patient with ovarian cancer previously treated with cisplatin". J. Clin. Oncol., 1991, 9, 389.
24. McGuire W.P., Ozols R.F.: "Chemotherapy of advanced ovarian cancer". Semin. Oncol., 1998, 25, 340.
25. Spriggs D.: "Optimal sequencing in the treatment of recurrent ovarian cancer". Gynecol. Oncol., 2003, 90, S39.
26. Barnes A.P., Miller B.E., Kucera G.L.: "Cyclooxygenase inhibition and hHyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells". Gynecol. Oncol., 2007, 104, 443.
27. Rubin S.C., Hoskins W.J., Hakes T.B., Markman M., Reichman B.S., Chapman D. et al.: "Serum CA125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1989, 7, 667. (Pubitemid 19092158)
28. Bese T., Demirkiran F., Arvas M., Oz A.U., Kosebay D., Erkun E.: "What should be the cut-off level of serum CA125 to evaluate the disease status before second look laparotomy in epithelial ovarian carcinoma?". Int. J. Gynecol. Cancer, 1997, 7, 42. (Pubitemid 27010016)
29. Rose P.G., Faulhaber P., Miraldi F., Abdul-Karim F.W.: "Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal ma: correlation with second-look laparotomy". Gynecol. Oncol., 2001, 82, 17. (Pubitemid 32634948)